Clinical Study
Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
Table 4
Univariate and multivariate analysis of disease control rate.
| Univariate analysis |
| | | Disease control rate |
| All Patients | |
23.2% (95% CI:18.9%–27.5%) |
| Sex | Male | 24% | P = .6 | Female | 22% | |
| Age (years) | 0–39 | 24% | P = .2 | 40–59 | 27% | | 60+ | 16% | |
| Histology | Leiomyosarcoma | 19% | P = .2 | Synovial sarcoma | 34% | P = .07 | Liposarcoma | 38% | P = .03 | Other | 19% | |
| Disease | Locally advanced | 18% | P = .1 | Metastatic—single organ | 29% | | Metastatic—multiple organs | 17% | |
| Sites of metastases | Involved versus uninvolved | | | Lung | 19% versus 29% | P = .04 | Liver | 27% versus 22% | P = .4 | Bone | 23% versus 23% | P = 1.0 |
| Chemotherapy | Single agent/Phase I | 21% | P = .02 | Combination | 36% | |
| Chemo Regimen | SA Doxorubicin | 27% | | SA Ifosfamide | 21% | | Other SA | 22% | | Phase I trial | 9% | | Dox/Ifos combination | 38% | | Other combination | 34% | |
| Multivariate analysis |
| | Relative likelihood of disease control (95% CI) | Significance |
| Pathology type | | | | Liposarcoma versus other |
2.5 | 1.2–5.1 | P = .02 | Synovial versus other |
2.3 | 1.2–4.5 | P = .02 |
| Sites of disease | | | | Lungs Involved |
0.6 | 0.3–1.0 | P = .04 |
| Not involved |
1.0 | Chemotherapy | | | | Single Agent/Phase 1 Combination |
1.0 | 1.2–4.4 | P = .01 |
2.3 |
|
|
SA: single agent, Dox/ Ifos: Doxorubicin/Ifosfamide.
|